

Real Time Material Information

This information is provided by 3176 Medigen Biotech Corp. (TPEX Listed Company)

Item	1	Announcement Date	2021/05/06	Announcement Time	16:55:20
Spokesperson	Arlene Chiang	Spokesperson Position	Assistant Vice President, Operations Department	Contact Information	[02]2653-5200#890
Subject	Update on the progress of the US clinical trial for the investigational new drug OBP-301 in patients with head and neck cancer				
Pursuant To Article	4	Subparagraph	53	Date of occurrence of event	2021/05/06
Details	<p>1. Date of occurrence of the event: 2021/05/06</p> <p>2. Company name: Medigen Biotechnology Corporation</p> <p>3. Relationship with the Company (please enter "the company itself" or "subsidiaries"): The Company itself.</p> <p>4. Reciprocal shareholding percentage: NA</p> <p>5. Cause of occurrence: OBP-301 (Telomelysin) is an oncolytic virus new drug jointly developed by Medigen Biotech Corp. and Oncolys BioPharma Inc., a Japanese listed company (TSE:4588). Oncolys announced on May 6 that the first patient has been enrolled today in the US investigator-initiated phase 2 clinical trial for head and neck cancer. . This clinical trial consists of a combination of 3 therapies: OBP-301, pembrolizumab and stereotactic radiation. The study will be recruiting patients with recurrent and inoperable head and neck cancer, with the goal of improving quality of life and response rate to radiation therapy, and further evaluate whether the addition of an anti-PD-1 antibody can increase the clinical benefits of OBP-301 combined with stereotactic radiation therapy. The trial is divided into two stages and is estimated to enroll a total of 36 subjects. The current plan is to recruit 12 subjects in the first stage by 2022, and then reassess whether to continue the study.</p> <p>6. Countermeasures: None.</p> <p>7. Any other matters that need to be specified:</p> <p>(1) Other clinical trials in progress for OBP-301 include an investigator-initiated phase 2 clinical trial in the US of OBP-301 in combination with an immunosuppressive agent as a treatment for gastric cancer and esophageal cancer, and a phase 2 clinical trial of OBP-301 combined with pembrolizumab (anti-PD-1 antibody) for head and neck cancer. In addition, the licensee Chugai Pharmaceutical is carrying out a phase 2 clinical trial of OBP-301 in combination with radiation treatment for esophageal cancer in Japan.</p> <p>(2) The Company and Oncolys (Japan) jointly bear the R&D expenses of OBP-301 and share future benefits.</p> <p>(3) It takes considerable time and expenses to develop a new drug of which success cannot be guaranteed. Investors shall bear such investment risk that warrants careful assessment before making investment decisions.</p> <p>(4) Link to announcement by Oncolys (Japan): https://ssl4.eir-parts.net/doc/4588/tdnet/1960503/00.pdf</p>				

The above information is declared by the company in accordance with the regulations of the market it belongs to at the time, and released to the public through this system. The company shall hold sole responsibility if any false information is declared.